1. Home
  2. FFWM vs CBIO Comparison

FFWM vs CBIO Comparison

Compare FFWM & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Foundation Inc.

FFWM

First Foundation Inc.

HOLD

Current Price

$5.90

Market Cap

473.3M

Sector

Finance

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$18.57

Market Cap

557.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FFWM
CBIO
Founded
1990
2003
Country
United States
United States
Employees
485
44
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
473.3M
557.8M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
FFWM
CBIO
Price
$5.90
$18.57
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$6.17
$26.67
AVG Volume (30 Days)
4.3M
305.9K
Earning Date
04-29-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$34,373,000.00
N/A
Revenue This Year
$56.34
N/A
Revenue Next Year
$10.68
$279.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.59
$8.72
52 Week High
$6.72
$27.41

Technical Indicators

Market Signals
Indicator
FFWM
CBIO
Relative Strength Index (RSI) 51.22 46.20
Support Level $5.44 $10.83
Resistance Level $5.97 $20.58
Average True Range (ATR) 0.19 2.40
MACD 0.03 -0.34
Stochastic Oscillator 80.63 41.53

Price Performance

Historical Comparison
FFWM
CBIO

About FFWM First Foundation Inc.

First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: